EXCLUSIVE: Retired David Mather was dealt a shocking blow when told his tiredness was stage-IV lung cancer - now a new UK ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...

Cedars-Sinai investigators are developing a tool using artificial intelligence to help predict pancreatic cancer in Black ...

Pancreatic cancer can cause back pain that spreads from the abdomen. It often affects the middle of the back and may feel like a dull ache. For some people, the pain may come and go. Pancreatic ...

From left: Triple Eight manager Mark Dutton, co-owner Earl Evans, Ford Australia CEO Andrew Birkic and motorsport engineering lead Brendan McGinniskin Friday’s announcement that current ...

As Trump’s new 10 percent tariffs on all Chinese imports took effect, China hit back with tariffs and sanctions of its own. On February 1, U.S. President Donald Trump announced that his ...

An emotional Triple H bid goodbye to one of the all-time greats from the Royal Rumble Premium Live Event as he wouldn't compete at the marquee show ever again. The Cenation Leader entered the ...

The liver produces CRP, an acute-phase protein, in response to the pro ... such as measuring pancreatic attenuation through non-enhanced CT images with three regions of interest (ROIs) on the head, ...

This paper presents a current stress optimized strategy for the DAB converter with triple-phase-shift and variable DC-Link voltage control (TPS-VDLC). Firstly, the TPS modulation scheme and variable ...

Triple Eight will switch to Ford in 2026. It tells us a lot about Triple Eight, Ford and General Motors, and their respective positions in the current Supercars ecosystem. Triple Eight is about ...

All products featured on Bon Appétit are independently selected by our editors. However, when you buy something through the retail links below, we earn an affiliate commission.

Canaccord rates Opthea a buy with target of $1.25 – $3 if Phase III trial is successful Opthea’s lead drug shows strong promise in eye disease trials Positive phase III results could lead to big gains ...